Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for ABCL575 in Moderate-to-severe atopic dermatitis (AD). The expected timing is based on the latest available company guidance and may change.
5/30/25- Received Health Canada trial approval and to initiate trial in Q3 2025. 8/27/25- First patient dosed. Data expected in Mid-2026. 11/06/25:- ABCL575 continues progressing through Ph1 trial; Ph1 data still expected in Mid-2026. 02/24/26:- Phase 1 trial progress reiterated; Phase 1 data still expected Mid-2026. 08/05/26:- Dosing completed; Phase 1 top-line data expected Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.